CA-TULA-TECHNOLOGY,-INC.
Jacobs Vehicle Systems and Tula Technology have signed a cooperation agreement to accelerate the development of Jacobs Cylinder Deactivation® (CDA® ) valve actuation technology in conjunction with Tula’s Dynamic Skip Fire (DSF® ) control algorithms. The agreement builds on two years of research and development collaboration between the two companies to reduce nitrous oxide (NOX ) and carbon dioxide (CO2 ) emissions from medium and heavy-duty vehicles, helping to meet ever-tightening environmental regulations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210915005336/en/
“Jacobs Vehicle Systems and Tula Technology are both great companies with great technologies, and we’ve been even more effective working together,” said John Fuerst, senior vice president of technology and innovation at Tula. “This agreement will advance our capabilities to produce better CDA products and dDSF controls.”
Independent laboratory testing has demonstrated that Jacobs CDA hardware and Tula’s dDSF achieve greater emission reductions when combined. Low-load cycle performance was estimated with a well-calibrated powertrain simulation tool to accurately capture the low-load system operation and emissions. This system showed as much as a 5% decrease in CO2 and a 74% reduction in NOX emissions compared to the baseline technology.
“While CDA and dDSF are available to commercial powertrain manufacturers as separate systems, our experience indicates that integrating the two technologies delivers much greater benefit to today’s medium- and heavy-duty engines,” said Steve Ernest, vice president of engineering and business development at Jacobs Vehicle Systems. “We have been working with Tula for several years, and this formal agreement solidifies our relationship as we demonstrate the benefits of using CDA and dDSF in tandem. Our efforts will provide the marketplace with sought-after solutions to meet increasingly challenging emissions standards. The synergies created through multiple development projects will offer customers the best possible outcomes for reducing NOX and CO2 simultaneously.”
The agreement will allow technical development to expand the operating range at which emissions reductions can be achieved when the two technologies are combined. Jacobs and Tula also will explore opportunities for reduced NOX and CO2 emissions in off-road vehicles and equip a Class 8 demonstrator truck with both Jacobs’ CDA and Tula’s diesel DSF technologies for customers to experience firsthand.
About Jacobs Vehicle Systems
Jacobs Vehicle Systems is headquartered in Bloomfield, Conn., where it has a 25,000 square meter design, testing, and manufacturing facility, with support sites in Europe, Japan, and India as well as manufacturing facilities in Suzhou, China, and Brno, Czech Republic. Jake Brake® products are used by heavy and medium-duty diesel engine manufacturers globally. Registered to the ISO 14001 and IATF16949 standards, Jacobs Vehicle Systems is a leading producer of vehicle retarding and valve actuation technologies and can be found at jakebrake.com .
About Tula Technology, Inc.
Silicon Valley-based Tula Technology provides innovative award-winning software controls to optimize propulsion efficiency and emissions across the mobility spectrum, including gasoline-powered, diesel, alternative fuel, hybrid, and electric vehicles. Tula’s culture of innovation has resulted in breakthrough technology and a robust global patent portfolio of more than 378 patents issued and pending. Tula Technology is a privately held company backed by Sequoia Capital, Sigma Partners, Khosla Ventures, GM Ventures, BorgWarner and Franklin Templeton. More information is available at www.tulatech.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005336/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom